ERBB2 and breast carcinoma: To investigate the mechanism by which EGF reduces binding of T-DM1 to cell surface HER2, which may lead to HER2-positive breast cancer cells resistance to T-DM1, we examined protein levels of HER2 in SKBR-3 cells treated with EGF, erlotinib or left untreated.